Occurrence, recurrence, and prognosis of hyperkalaemia in a large real-world cohort

Clicks: 31
ID: 325998
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #34 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Hyperkalaemia (HK), a common electrolyte abnormality, often occurs in patients with other comorbidities. This study assessed the occurrence, recurrence, and prognosis of HK in a real-world setting. Methods In this single-center, retrospective study (January 2018–December 2021), patients aged ≥ 18 years who had serum potassium (sK+) > 5.0 mmol/L at least once and who visited Ren Ji Hospital were analyzed for prevalence, recurrence and real-world cumulative survival. Results Of 55 288 patients screened, 1 141 (2.1%) had HK. Overall, 1 131 (2.0%) patients were enrolled with a mean age of 68 ± 16.7 years, the majority being men (57.6%), and with median sK+ levels of 5.40 (5.2–5.8) mmol/L; most patients had mild HK (62.6%). The cumulative 1-year survival rate was 81.5%. Recurrence of HK occurred in 25.8% of patients, with a median (interquartile range) time of 35 (7–192) days. The time to first re-examination was < 7 days in 55.1%, <30 days in 61.1%, <90 days in 63.7%, and > 90 days in 4.9%. Hypertension (49.4%) was the most common comorbidity, followed by diabetes, coronary artery disease, and malignancy. High usage of β-blockers (17.6%), followed by ACEIs/ARB, aldosterone receptor antagonists, and non-steroidal anti-inflammatory drugs, was observed. All-cause mortality was 20.2%, significantly higher in moderate-to-severe HK compared with mild HK. Risk factors associated with all-cause mortality included sK+ levels (per 1 mmol/L increase) (hazard ratio [HR]: 1.328) and anemia (HR: 2.027). Conclusions HK is common among real-world patients in a large tertiary centre in China, with high recurrence rates and poor clinical prognosis. As a substantial proportion of patients did not undergo repeat sK⁺ measurement, the recurrence rate reported here likely underestimates the true real-world burden of recurrent HK.
Reference Key
openalex_W7203970112 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Haijiao Jin, Fan Yang, Renhua Lu, Yijun Zhou, Zanzhe Yu, Xinghua Shao, Jiaqi Gu, Leyi Gu, Zhaohui Ni
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag210
URL
https://doi.org/10.1093/ckj/sfag210
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.